At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 216 enrolled
Drug / intervention
Sitravatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Sitravatinib and Tislelizumab for Advanced Solid Tumors. Completed, enrolled 216 participants across 19 sites in 2 countries.
Detailed Summary
This was an open-label, multicenter, non-randomized Phase 1b clinical trial for participants with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ovarian cancer (OC), or melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesAustralia, China
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionJan 2023
TodayJul 2026
First PostedSep 11, 2018
Enrollment StartNov 1, 2018
Primary CompletionJan 5, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.8 years ago
Interventions
Sitravatinibdrug
Administered orally as a capsule
Tislelizumabdrug
Administered intravenously